Hyperglycaemic conditions perturb mouse oocyte in vitro developmental competence via beta-O-linked glycosylation of Heat shock protein 90 by Frank, L. et al.
 ACCEPTED VERSION  
 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
Human Reproduction following peer review. The definitive publisher-authenticated version 
 Frank, L.; Sutton-McDowall, M.; Brown, H.; Russell, D.; Gilchrist, R.; Thompson, J.  
Hyperglycaemic conditions perturb mouse oocyte in vitro developmental 
competence via beta-O-linked glycosylation of Heat shock protein 90, Human 





© The Author 2014. Published by Oxford University Press on behalf of the European 
























http://www.oxfordjournals.org/access_purchase/self-archiving_policyb1.html    
Policy B1 
AUTHOR SELF-ARCHIVING POLICY 
 Authors may upload their accepted manuscript PDF ("a post-print*") to institutional 
and/or centrally organized repositories, but must stipulate that public availability be 
delayed until 12 months after first online publication in the journal. Please note that a 








Hyperglycaemic conditions perturb mouse oocyte in vitro developmental competence via beta-
O-linked glycosylation of Heat shock protein 90 
Running title  




, M. L. Sutton-McDowall
1
, H. M. Brown
1
, D. L. Russell
1
, R. B. Gilchrist
1





The Robinson Institute, School of Paediatrics and Reproductive Health, The University of 
Adelaide. Ground Floor, Norwich Centre, 55 King William Road, North Adelaide, SA 5006, 
Australia. 
*
Corresponding author jeremy.thompson@adelaide.edu.au 
2 
 
Abstract  2 
Study question: What is the effect of beta-O-linked glycosylation (O-GlcNAcylation) on 3 
specific  proteins in the cumulus-oocyte complex (COC) under hyperglycaemic conditions?  4 
Summary answer: Heat shock protein 90 (HSP90) was identified and confirmed as being O-5 
GlcNAcylated in mouse COCs under hyperglycaemic conditions (modelled using glucosamine), 6 
causing detrimental outcomes for embryo development.  7 
What is known already: O-GlcNAcylation of proteins occurs as a result of increased activity of 8 
the hexosamine biosynthesis pathway, which provides substrates for cumulus matrix production 9 
during COC maturation, and also for O-GlcNAcylation. COCs matured under hyperglycaemic 10 
conditions have decreased developmental competence, mediated at least in part through the 11 
mechanism of increased O-GlcNAcylation.  12 
Study design, size, duration: This study was designed to examine the effect of hyperglycaemic 13 
conditions (using the hyperglycaemic mimetic, glucosamine) on O-GlcNAc levels in the mouse 14 
COC, and furthermore to identify potential candidate proteins which are targets of this 15 
modification, and their roles in oocyte maturation.   16 
Participants/materials, setting, methods:  17 
COCs from 21-day old superovulated CBA x C57BL6 F1 hybrid female mice were matured in 18 
vitro (IVM). Levels of O-GlcNAcylated proteins, HSP90 and O-GlcNAc transferase (OGT, the 19 
enzyme responsible for O-GlcNAcylation) in COCs were measured using Western blot, and 20 
localization observed using immunocytochemistry. For glycosylated HSP90 levels, and to test 21 
OGT-HSP90 interaction, immunoprecipitation was performed prior to Western blotting. Embryo 22 
development was assessed using in vitro fertilization and embryo culture post-maturation. 23 
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Main results and the role of chance: Addition of the hyperglycaemic mimetic glucosamine to 24 
IVM medium for mouse COCs increased detectable O-GlcNAcylated protein levels (by Western 25 
blot and immunocytochemistry), and this effect was reversed using an OGT inhibitor (P < 0.05). 26 
HSP90 was identified as a target of O-GlcNAcylation in the COC, and inhibition of HSP90 27 
during IVM reversed glucosamine-induced decreases in oocyte developmental competence (P < 28 
0.05). We also demonstrated the novel finding of an association between HSP90 and OGT in 29 
COCs, suggesting a possible client-chaperone relationship. 30 
Limitations, reasons for caution: In vitro maturation of COCs was used so that treatment time 31 
could be limited to the 17 h of maturation prior to ovulation. Additionally, glucosamine, a 32 
hyperglycaemic mimetic, was used because it specifically activates the hexosamine pathway 33 
which provides the O-GlcNAc moieties. The results in this study should be confirmed using in 34 
vivo models of hyperglycaemia and different HSP90 inhibitors.  35 
Wider implications of the findings: This study leads to a new understanding of how diabetes 36 
influences oocyte competence and provides insight into possible therapeutic interventions based 37 
on inhibiting HSP90 to improve oocyte quality. 38 
Study funding/competing interest(s):  39 
This work was supported by a Program Grant from the National Health and Medical Research 40 
Council, Australia, ID 453556. J. G. T. is a recipient of funding from and a consultant to Cook 41 
Medical Pty Ltd. The other authors have no conflicts of interest to declare. 42 
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Reversible beta-O-linked glycosylation of proteins (the addition of N-acetylglucosamine; O-47 
GlcNAcylation) is gaining recognition as an important regulatory mechanism of cytosolic and 48 
nuclear proteins (Van den Steen et al. 1998; Slawson, Housley, and Hart 2006; Wells, Whelan, 49 
and Hart 2003). O-GlcNAcylation regulates protein function in a manner similar to 50 
phosphorylation, with the two modifications often targeting the same or adjacent sites on a 51 
protein in what has been described as a yin-yang relationship (Comer and Hart 2000; Butkinaree, 52 
Park, and Hart 2010; Wang, Gucek, and Hart 2008; Haltiwanger et al. 1997; Whelan and Hart 53 
2003). O-GlcNAcylation is involved controlling essential cellular processes such as cell cycle 54 
regulation (Slawson and Hart 2003; Slawson et al. 2002; Haltiwanger and Philipsberg 1997; 55 
Drougat et al. 2012), protein transcription and translation (Comer and Hart 2000; Datta et al. 56 
2001) and DNA damage/repair pathways (Zachara et al. 2011). It is implicated in a myriad of 57 
disease states including cancer, inflammatory conditions and neurodegenerative diseases (Hart, 58 
Housley, and Slawson 2007; Slawson and Hart 2011). Some O-GlcNAc modifications are 59 
necessary for cell viability in mammals (Vocadlo et al. 2003; O'Donnell et al. 2004). However, 60 
excessive O-GlcNAcylation or inhibition of the removing enzyme beta-N-acetylglucosaminidase 61 
(O-GlcNAcase) is often detrimental to cell survival and function (Marshall, Bacote, and 62 
Traxinger 1991; McClain et al. 2002; Arias, Kim, and Cartee 2004; Yang et al. 2008). 63 
Conversely, too little O-GlcNAcylation can also disrupt normal cellular function (Liu et al. 2004; 64 
Yuzwa et al. 2011). 65 
In contrast with glycosaminoglycan-type glycosylation, the O-GlcNAc modification consists of a 66 
single beta-O-linked N-acetylglucosamine residue, and no chain is formed by addition of further 67 
residues. First discovered in 1984 (Torres and Hart 1984), it is now estimated that O-68 
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GlcNAcylation is as widespread as phosphorylation, and has been found in all multicellular 69 
eukaryotes examined to date (Wells, Vosseller, and Hart 2001; Comer and Hart 2000; 70 
Roquemore, Chou, and Hart 1994). However, the role of O-GlcNAc in various systems, 71 
including the reproductive system, is only now starting to be characterized because of its 72 
comparatively recent discovery as well as the technical difficulties associated with studying it 73 
(Whelan and Hart 2003). In somatic cells, under normoglycaemic conditions approximately 1 – 74 
3% of total glucose consumed by the cell is directed down the hexosamine biosynthesis pathway 75 
(HBP) (Sayeski and Kudlow 1996; Marshall, Bacote, and Traxinger 1991), which produces 76 
UDP-GlcNAc, the substrate for O-GlcNAcylation (Marshall, Nadeau, and Yamasaki 2004). The 77 
HBP was first implicated in the development of type 2 diabetes in 1991 (Marshall, Bacote, and 78 
Traxinger 1991), and it has now been shown to play a significant role in both the major 79 
pathologies of diabetes: insulin resistance and the decline in pancreatic beta-cell function (Yang 80 
et al. 2008; Marshall, Bacote, and Traxinger 1991). Increasing flux through the pathway, raising 81 
O-GlcNAc levels using PUGNAc (O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-82 
phenylcarbamate), an inhibitor of O-GlcNAcase), or overexpression of the transfer enzyme beta-83 
O-linked N-acetylglucosamine transferase (OGT), all result in insulin resistance (Arias and 84 
Cartee 2005; Arias, Kim, and Cartee 2004; McClain et al. 2002; Vosseller et al. 2002; Akimoto 85 
et al. 2007).  86 
It is well established that maternal diabetes is associated with poor conception rates and 87 
difficulties with maintenance of a pregnancy and delivery of a healthy baby (Becerra et al. 1990; 88 
Holing et al. 1998; Lapolla, Dalfra, and Fedele 2008; Purcell and Moley 2011; Jungheim and 89 
Moley 2010; Rich-Edwards et al. 1994).In studies of diabetic women, even if optimal glycaemic 90 
control is achieved within the first few weeks of pregnancy (embryonic and early fetal 91 
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development), there is still a 3 – 5 times higher risk of spontaneous abortions and congenital 92 
anomalies in these women (El-Sayed and Lyell 2001; Casson et al. 1997; Baccetti et al. 2002). 93 
However, if a pre-conception treatment program is undertaken this risk is significantly reduced 94 
(Dunne et al. 1999; Pearson et al. 2007; Ray, O'Brien, and Chan 2001), implicating the period of 95 
oocyte maturation as a critical window of oocyte susceptibility to damage. 96 
Many studies examining the role of the HBP use glucosamine as a hyperglycaemic mimetic, as it 97 
is specifically metabolised by the HBP, enters the pathway downstream of the rate-limiting 98 
enzyme glutamine:fructose-6-phosphate amidotransferase (Patti et al. 1999; Marshall, Nadeau, 99 
and Yamasaki 2005; Nelson, Robinson, and Buse 2000) and hence is a potent stimulator. Using 100 
this treatment, mouse embryos exposed from the zygote stage in vitro to 27 mM glucose 101 
(approximately the blood glucose level of diabetic mice, vs. normoglycaemic ~8 mM (Chu et al. 102 
2006; Fox et al. 2011; Ozcan et al. 2006)) or 0.2 mM glucosamine have been shown to produce 103 
fewer blastocysts, with reduced cell numbers compared to controls, and an increase in apoptosis 104 
(Pantaleon et al. 2010). Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP), an 105 
inhibitor of OGT, was able to reduce all of these effects.  106 
Consistent with these findings, peri-conception glucosamine treatment in mice in vivo causes a 107 
range of defects (reduced litter size, increased congenital abnormalities and reduced fetal weight) 108 
depending on the age of the mother (Schelbach et al. 2013). In vitro, O-GlcNAcylation is 109 
elevated in bovine cumulus-oocyte-complexes (COCs) exposed to glucosamine (Sutton-110 
McDowall et al. 2006) and while glucosamine treatment during IVM does not affect meiotic 111 
maturation of cow, pig or mouse oocytes, blastocyst development was severely inhibited (Sutton-112 
McDowall et al. 2006; Schelbach et al. 2010). A decrease in cleavage rate was also observed in 113 
the mouse study in the presence of glucosamine (Schelbach et al. 2010). BADGP in IVM media 114 
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was able to rescue embryo development from COCs cultured in the presence of glucosamine in a 115 
dose-dependent manner, highlighting the contribution of the HBP to the developmental 116 
competence of these oocytes. Recently, in our laboratory we have shown that flux through the 117 
HBP during the first hour of IVM appears to be critical for developmental competence, whereas 118 
high levels of glucosamine supplementation alone (in the absence of glucose) throughout IVM 119 
were detrimental to competence measures (Frank et al. 2013). These results support the concept 120 
that an intermediate level of HBP flux is optimal.  121 
Given the important role of HBP in oocyte developmental competence, the aim of the current 122 





CBA x C57BL6 F1 hybrid mice (females 21 days old, males 6 – 8 weeks old) were maintained 128 
in the Animal House at the Medical School, The University of Adelaide, under a 14:10 hour 129 
light:dark cycle with ad libitum access to food and water.  130 
Ethical approval 131 
All experimental procedures were carried out in accordance with the Australian Code of Practice 132 
for the Care and Use of Animals for Scientific Purposes, and approved by The University of 133 
Adelaide Animal Ethics Committee (Medical). 134 
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Chemicals  135 
Unless otherwise specified all reagents and antibodies were purchased from Sigma-Aldrich (MO, 136 
USA). BAGDP and 17-(Allylamino)-17-demethoxygeldanamycin (17AAG; A.G. Scientific, CA, 137 
USA) were dissolved and stored in DMSO at -80C. The final concentration of DMSO in culture 138 
media for each was 0.27% and 0.01% respectively.  139 
Media 140 
All media used were as previously described (Frank et al. 2013). Briefly, simple mouse IVM 141 
media supplemented with fatty acid-free bovine serum albumin (BSA; ICPbio, Glenfield, New 142 
Zealand) were used for collection and IVM of COCs, with 50 mIU/mL recombinant human 143 
follicle-stimulating hormone (Organon, Oss, The Netherlands) added to maturation media only. 144 
Media used for embryo development experiments were also supplemented with 1 mg/ml fetuin 145 
to prevent zona hardening. For embryo production following IVM, Research Vitro Wash, 146 
Fertilization and Cleave media were used (Cook Medical, QLD, Australia). Maturation and 147 
embryo culture media were pre-equilibrated for at least 4 h prior to use at 37 °C in a humidified 148 
6% CO2 atmosphere, and collection medium pre-warmed to 37 C. Where media was 149 
supplemented with glucosamine, a dose of 2.5 mM was used. This has been shown in previous 150 
studies to be an effective inhibitory dose for mouse in vitro COC culture at the volumes and 151 
levels of glucose (5.6 mM) used and it induces a significant decrease in subsequent blastocyst 152 
rate and meiotic completion but does not totally ablate development (Schelbach et al. 2010; 153 
Frank et al. 2013). 154 
COC collection and IVM 155 
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Female mice were administered 5 IU equine chorionic gonadotrophin (eCG; Folligon, Intervet, 156 
Boxmeer, The Netherlands) as an intraperitoneal injection. 46 h post-eCG injection, ovaries were 157 
collected, COCs were aspirated and were held in collection medium for one hour. COCs were 158 
washed once in collection medium, once in maturation medium and matured for up to 18 h in a 159 
volume of 50 µL medium/COC at 37 °C under paraffin oil, in humidified air comprising 6% 160 
CO2/5% O2/89% N2. 161 
In vitro fertilisation and embryo culture 162 
In vitro fertilisation (IVF) and embryo culture were carried out as described previously (Frank et 163 
al. 2013). Briefly, after 17 h of maturation COCs were placed in fertilisation medium for 4 h with 164 
sperm which had been allowed to capacitate for 1 hour prior to co-incubation. Presumptive 165 
zygotes were transferred to culture drops, cleavage rate assessed on Day 2 of culture and embryo 166 
developmental stage assessed on Day 5.  167 
Immunoprecipitation 168 
COC samples for immunoprecipitation were processed by adding a 1:9 Protease Inhibitor 169 
Cocktail (PIC): radioimmunoprecipitation assay (RIPA) buffer solution and antibody and 170 
incubating with rotation overnight at 4 °C (RIPA buffer: 10 mM Tris, 150 mM NaCl, 1 mM 171 
EDTA, 1% Triton X-100 (USB Corporation, OH, USA)). For immunoprecipitation, 0.6 µL 172 
CTD110.6 (anti-O-GlcNAc antibody; Covance, NJ, USA) was used per 50 COCs or 2 µL anti-173 
OGT per 50 COCs.  On day 2 of the protocol, 10 µL Protein L beads (Thermo Fisher Scientific, 174 
MA, USA) were added to each sample and rotated at 4 C for a further 4 - 5 h. Samples were 175 
then washed and centrifuged three times at 20,000 g for two minutes (Eppendorf Centrifuge 176 
5424, Hamburg, Germany) with RIPA buffer to remove all supernatant. Beads were boiled in 1 x 177 
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Laemmli buffer (LB; 50% glycerol, 10% SDS, 0.5% bromophenol blue, 250 mM Tris, 10% β-178 
mercaptoethanol added immediately before use) for 7 minutes and centrifuged, and the 179 
supernatant used for Western blotting. 180 
Western blots 181 
For all Western blots, samples were lysed in the PIC:RIPA mixture, LB added and samples 182 
boiled for 7 minutes. Proteins were then separated on a 7.5% SDS-PAGE gel and wet-transferred 183 
to a polyvinylidene fluoride membrane (GE Healthcare, Little Chalfont, UK) overnight. 184 
Molecular weight markers were Precision Plus Protein Dual Color Standards (Bio-Rad, CA, 185 
USA).  186 
O-GlcNAc blots 187 
Blocking and washing solutions and protocol were as described previously (Zachara et al. 2002), 188 
using 1/1000 CTD110.6 (anti-O-GlcNAc) and 1/2500 alkaline phosphatase-conjugated anti-189 
mouse IgM (Rockland, PA, USA). Blots included BSA-conjugated-N-acetylglucosamine (BSA-190 
GlcNAc) as a positive control (5 ng unless otherwise specified) and 100 ng of each of BSA (not 191 
glycosylated) and ovalbumin (N-linked but not β-O-linked glycosylated) as negative controls. 192 
Control experiments were performed using competitive inhibition with 15.4mM free GlcNAc to 193 
further confirm specificity of CTD110.6 (not shown). Blots were developed using Western Blue 194 
Stabilized Substrate for Alkaline Phosphatase (Promega, WI, USA). Blots performed without 195 
immunoprecipitation were co-stained with horseradish peroxidase (HRP)-conjugated anti-beta-196 
actin as a loading control (1/1,000,000) and developed using the ECL system (GE Healthcare, 197 
Little Chalfont, UK) after colorimetric development. 198 
HSP90 blots 199 
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Membranes were blocked for one hour in 5% skim milk in Tris-buffered saline with Tween 20 200 
(TBST; 150 mM NaCl, 50 mM Tris-HCl, 0.05 % Tween 20, adjusted to pH 7.6), washed 3 x 5 201 
minutes with TBST, and incubated with 1/2500 pan anti-HSP90 (Becton Dickinson, NJ, USA; 202 
this antibody targets both alpha and beta isoforms of the protein) in 5% milk overnight at 4 °C. 203 
On day 2, membranes were washed as described above, incubated with 1/5000 HRP-conjugated 204 
goat polyclonal anti-mouse IgG in 5% milk at room temperature for 1 hour, washed again and 205 
developed using the ECL system (GE Healthcare, Little Chalfont, UK). Blots included 1 µg 206 
HeLa cell lysate (Enzo Life Sciences, NY, USA) as a positive control and were also stained with 207 
HRP-conjugated anti-beta-actin as a loading control (1/1,000,000). 208 
Immunocytochemistry 209 
COCs were collected at 6 h of maturation and fixed in 4% paraformaldehyde overnight. Whole 210 
COCs were adhered on Cell-Tak (Becton Dickinson, NJ, USA) –coated slides, permeabilised in 211 
0.25% Triton X-100 (USB Corporation, OH, USA), blocked for 2 h using 10% goat serum 212 
(Jackson ImmunoResearch, PA, USA) and 0.2% Tween 20 and incubated overnight at 4°C with 213 
1/250 primary antibody (CTD110.6  for anti-O-GlcNAc, anti-HSP90 or anti-OGT) in blocking 214 
solution. On day 2 COCs were washed and incubated for 2 h with 1/250 secondary antibody 215 
(Alexa Fluor 488 goat anti-mouse IgM (Life Technologies, CA, USA) or goat anti-rabbit IgG 216 
(Abcam, Cambridge, UK), Alexa Fluor 594 goat anti-mouse IgG or donkey anti-goat IgG 217 
(Abcam), and counter-stained for 30 minutes with propidium iodide (PI) or 4’,6-diamidino-2-218 
phenylindole (DAPI), mounted under a coverslip and examined on an Olympus Fluoview FV10i 219 
laser scanning confocal microscope (Olympus, Tokyo, Japan). All colours for images were 220 
collected simultaneously, and laser intensity settings remained uniform. Excitation/emission 221 
wavelengths in nm were 559/619, 405/461, 473/520 and 559/618 for PI, DAPI, Alexa Fluor 488 222 
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and Alexa Fluor 594 respectively. A 60 x objective lens, type UPLSAP60xW, was used with 0 – 223 
8.5 digital zoom (for individual magnifications see figure legends). For quantitative assessment 224 
of fluorescence, the mean gray scale intensity of an area of defined size was measure per COC. 225 
To ensure consistency this area was centred over and included the entire ooctye for each picture. 226 
For competitive inhibition in Experiment 2, the primary antibody step was performed in the 227 
presence of 15.4 mM free GlcNAc. 228 
Silver staining and mass spectrometry 229 
Samples were separated on a 7.5% SDS-PAGE gel as described for Western blotting, and stained 230 
using the SilverQuest Silver Staining Kit (Invitrogen, CA, USA) which is compatible with mass 231 
spectrometry. Gels were provided to the Adelaide Proteomics facility (The University of 232 
Adelaide, SA, Australia) where specific bands were excised, destained and analysed using liquid 233 
chromatography-electrospray ionisation ion-trap mass spectrometry, to identify potential O-234 
GlcNAcylation targets. Using this method, each time a peptide is matched to a protein, it is given 235 
a score based on the degree of homology with the identified protein. The Combined Ion Score is 236 
the sum of all these individual matches for each protein; the higher the score, the more likely that 237 
the identified protein was present in the sample analysed.  238 
Statistical analyses 239 
Data were analysed using SPSS version 18.0.2 (Predictive Analytics Software, IBM, NSW, 240 
Australia). Quantification of protein bands on Western blots was performed using ImageJ 241 
version 1.44p (Rasband 1997 - 2012). Data were tested for normality using the Shapiro-Wilk test 242 
and, if normally distributed, analysed using a one-way analysis of variance (ANOVA) and 243 
comparisons made by least-significant difference post-hoc test. Data which were not normally 244 
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distributed were analysed using a Kruskal-Wallis test followed by Mann-Whitney U tests if 245 
significance was found. A P value of < 0.05 was accepted as significant. Embryo development 246 
data were assessed using Chi Square analysis.  247 
Results 248 
Experiment 1: Western blot analysis of O-GlcNAcylation levels in the COC during IVM 249 
Groups of 50 COCs were collected at 6 h of culture and snap frozen. Control group COCs were 250 
matured in standard media. Groups 2 and 3 were treated with 2.5 mM glucosamine in maturation 251 
medium, and group 3 also included 2.5 mM of the OGT inhibitor BADGP. Data from 252 
preliminary experiments (Supp. Fig. 1) showed that throughout IVM (6, 12 and 18 h), 253 
glucosamine treatment increased O-GlcNAcylation within the COC. The increase relative to the 254 
control was greatest at 6 h of maturation, therefore this time point was used for the experiments 255 
discussed here. Proteins from COCs collected at the 6 h time point (Fig. 1) showed a pattern of 256 
increased O-GlcNAcylation with glucosamine treatment (P < 0.05 compared to control, n = 4 257 
replicates) which was reduced with the addition of BADGP (P < 0.05).  258 
Experiment 2: Immunocytochemical analysis of O-GlcNAcylation levels in the COC at 6 h IVM  259 
Treatment groups for Experiment 2 were as described in Experiment 1. Immunocytochemical 260 
localisation of O-GlcNAc with the CTD110.6 antibody in whole COCs collected after 6 h of 261 
culture revealed extensive positive staining in the cumulus cells (Fig. 2; representative images 262 
from n = 3). Compared to the control group, staining intensity increased in COCs treated with 263 
glucosamine (2.3-fold higher, P < 0.05) and this increase was eliminated to control levels by co-264 
treatment with BADGP (P < 0.05). For representative immunocytochemistry controls please see 265 
Supplementary Figure 2. 266 
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Experiment 3: Identification of specific proteins which are O-GlcNAcylated in glucosamine-267 
treated COCs 268 
Immunoprecipitation of 100 glucosamine-treated COCs collected at 6 h of maturation was 269 
performed as described, and the immunoprecipitated product was separated on a 7.5% SDS-270 
PAGE gel which was then silver stained. Specific bands were excised, destained and analysed 271 
using liquid chromatography-electrospray ionisation ion-trap mass spectrometry to identify 272 
potential O-glycosylation targets. Mass spectrometry analysis revealed 15 potential targets of O-273 
glycosylation (Table 1). Eleven of these 15 proteins have been previously described in the 274 
literature as being O-GlcNAcylated, including HSP90, the alpha form of which had the highest 275 
Combined Ion Score of any protein identified in this experiment. One class of proteins which 276 
was well represented was structural proteins, with fibronectin, actin and tubulin identified, as 277 
well as several involved in protein folding including protein disulfide isomerase and protein 278 
disulfide isomerase A3, and both isoforms of HSP90 (alpha and beta). 279 
Experiment 4: Total and O-GlcNAcylated HSP90 in COCs after 6 h IVM 280 
HSP90 is a molecular chaperone which responds to cellular stress by stabilizing unfolded 281 
proteins and preventing their aggregation. Glucosamine is known to induce stress in various cell 282 
types, therefore the total levels of HSP90 in each treatment group were examined using Western 283 
blot analysis on COCs using treatment groups as described in Experiment 1. There was no 284 
difference in the total amount of HSP90 protein in COCs between treatment groups at 6h (Fig. 285 
3A, n = 3). However, when proteins were immunoprecipitated using CTD110.6 to pull down O-286 
glycosylated proteins and then detected with anti-HSP90, there was a dramatically higher level 287 
of O-glycosylated HSP90 found in COCs from the glucosamine treatment group, than either the 288 
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control or glucosamine + BADGP groups (Fig. 3B, n = 2). Co-localisation of HSP90 and O-289 
GlcNAcylation was observed in both the oocyte and cumulus cells (Fig. 3C; representative 290 
images from n = 3). For representative immunocytochemistry controls please see Supplementary 291 
Figure 2. 292 
Experiment 5: Effect of inhibition of HSP90 during IVM of COCs 293 
Previous work in our laboratory has shown that the presence of glucosamine during IVM 294 
significantly reduces oocyte developmental competence of several species including mice 295 
(Sutton-McDowall et al. 2006; Schelbach et al. 2010).  The amount of O-GlcNAcylated HSP90 296 
present in these COCs appears to be higher (Fig. 3B) than in those which are known to have 297 
good developmental competence (control and BADGP groups). Therefore it was hypothesised 298 
that inhibiting O-GlcNAcylated HSP90 during COC maturation would be beneficial to oocyte 299 
developmental competence. Control and glucosamine groups were as described for Experiment 300 
1; HSP90 inhibitor 17AAG was added to the maturation medium of groups 2 and 4 at a 301 
concentration of 0.1 µM.  Supplementing IVM media with 17AAG did not affect blastocyst 302 
development under control conditions (Fig. 4). However, when added to the group 303 
developmentally compromised by the hyperglycaemic mimetic glucosamine, 0.1 µM 17AAG 304 
was able to restore embryo development (57.3% vs. 76.7% respectively, P < 0.05, n = 3 with 305 
average 27 COCs/group/replicate). There was no difference in the cleavage rate between 306 
treatment groups. 307 
Experiment 6: Interaction of HSP90 with OGT 308 
To test for a direct interaction between HSP90 and OGT, proteins from COCs matured for 6h 309 
were immunoprecipitated using anti-OGT, then separated via SDS-PAGE and detected using 310 
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anti-HSP90. While a very small amount of HSP90 was detected in the no-antibody control 311 
immunoprecipitation, this was dramatically enriched in the immunoprecipitation using anti-OGT 312 
(Fig. 5A). Co-localisation of HSP90 and OGT was also observed in both the oocyte and cumulus 313 
cells using immunocytochemical staining (Fig. 5B; representative images from n = 2). For 314 
representative immunocytochemistry controls please see Supplementary Figure 2. 315 
Discussion 316 
In this study, we examined levels of O-GlcNAcylation on proteins within mouse COCs, 317 
identified HSP90 as a target protein, and investigated its potential role in oocyte maturation 318 
under hyperglyacemic conditions. Treatment with the hyperglycaemic mimetic glucosamine 319 
during IVM increased O-GlcNAcylated protein levels in COCs (by Western blot and 320 
immunohistochemistry), especially by 6h of maturation. Inhibition of O-GlcNAcylated HSP90 321 
(confirmed using immunoprecipitation and Western blot) during IVM was able to reverse 322 
glucosamine-induced decreases in oocyte developmental competence, suggesting an aberrant 323 
function of O-GlcNAcylated HSP90. Using immunoprecipitation, we demonstrated the novel 324 
finding of an association between HSP90 and OGT in COCs, suggesting that OGT may be a 325 
client protein of HSP90. When combined, these results reveal that glucosamine treatment caused 326 
O-GlcNAcylation of HSP90, with negative consequences for subsequent embryo development. 327 
We chose a 6h time-point to examine differences in O-linked glycosylation across treatments, as 328 
this time-point appeared to be a particularly active period for this post-translation protein 329 
modification in the presence of glucosamine.  We acknowledge that the results reported here 330 
may differ if we had chosen other time points.      331 
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It is well documented that glucosamine treatment or PUGNAc increases O-GlcNAc levels 332 
detectable by Western blot in other cell types including the Jurkat (human T lymphocyte) cell 333 
line (Comer et al. 2001), rat skeletal muscle, liver (Arias and Cartee 2005) and neonatal 334 
cardiomyocytes (Champattanachai, Marchase, and Chatham 2008). Increased O-GlcNAc levels 335 
have also been observed in the pancreas of Goto-Kakizaki rats (a type 2 diabetic model) 336 
compared to control rats (Akimoto et al. 2007). The results of the present study support these 337 
observations, as glucosamine increased detectable O-GlcNAcylation levels, shown by Western 338 
blot and immunocytochemistry. Glucosamine supplementation, which led to the highest level of 339 
O-GlcNAcylation in these experiments, significantly reduces blastocyst formation following 340 
oocyte IVM in mouse, pig and cow (Sutton-McDowall et al. 2006; Schelbach et al. 2010). 341 
Similarly, co-culture with BADGP and glucosamine during IVM reduced O-GlcNAcylation 342 
levels in COCs and rescued embryo development. Together these results suggest that increased 343 
levels of O-GlcNAcylation in COCs are associated with reduced oocyte developmental 344 
competence. A similar phenomenon has been seen in pancreatic β-cells. When O-GlcNAcylation 345 
was increased in β-cells following glucosamine or streptozotocin (diabetes-inducing) treatment, 346 
cell viability was decreased. The combination of glucosamine and streptozotocin treatment 347 
further reduced the percent of viable cells (Park et al. 2007). Our results are consistent with all of 348 
these studies, providing further evidence for the detrimental effect of excess O-GlcNAcylation 349 
on cellular function. 350 
In mouse COCs matured in control medium (5.55 mM glucose) there were still detectable levels 351 
of O-GlcNAcylation. This result supports previous findings that some O-GlcNAcylation is 352 
necessary for normal cellular function (Slawson et al. 2005), including the detection in bovine 353 
COCs of O-GlcNAc in the control group (Sutton-McDowall et al. 2006).  354 
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Using immunocytochemistry, in all groups proteins within the oocyte itself appear to be 355 
positively stained for O-GlcNAcylation. While this staining appears to increase with 356 
glucosamine treatment, neither BADGP nor competitive inhibition of CTD110.6 was able to 357 
decrease it. This result is in contrast to that previously shown by Sutton-McDowall et al. (Sutton-358 
McDowall et al. 2006), who found staining for O-GlcNAcylation in the cumulus cells but not the 359 
oocyte in bovine COCs. Supporting this, a previous study demonstrated that effect of 360 
glucosamine on blastocyst development was mediated by the cumulus cells, with denuded mouse 361 
oocytes not responding to glucosamine treatment compared to control medium (Schelbach et al. 362 
2010). A possible explanation for the difference observed in immunocytochemical staining could 363 
be the different antibodies used (bovine, RL2), or it may be a species difference between mouse 364 
and bovine COCs (either the amount of O-GlcNAcylation in the oocyte or the efficiency of 365 
detection).   366 
Immunoprecipitation of proteins using the CTD110.6 antibody to capture O-GlcNAcylated 367 
proteins in glucosamine-treated COCs, followed by mass spectrometry, revealed 15 candidate 368 
proteins. While validation of the O-GlcNAcylation status of all the proteins was beyond the 369 
scope of this study, four of these have not been previously reported as O-GlcNAcylated in the 370 
literature and are potential novel targets. 371 
Several of the identified proteins, such as fibronectin, actin and tubulin-α, are structural proteins. 372 
Fibronectin levels correlate with follicular size and oocyte maturity in human follicular fluid and 373 
when the cell-binding capacity of fibronectin is inhibited, this prevents both spontaneous and 374 
gonadotrophin-releasing hormone (GnRH)-induced resumption of meiosis as well as cleavage in 375 
mouse oocytes (Hung, Tsuiki, and Yemini 1989). Fibronectin also promotes bovine embryo 376 
development in serum-free medium (Larson, Ignotz, and Currie 1992). Actin is an important 377 
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component of the cytoskeleton and interestingly is known to influence the remodelling of 378 
connexin-43 gap junctions (Theiss and Meller 2002), vital for folliculogenesis in the mouse 379 
(Ackert et al. 2001). Gap junctional communication is impaired in cultured astrocytes injected 380 
with anti-actin antibodies (Theiss and Meller 2002), which suggests a possible role for O-381 
GlcNAcylation of actin in the COC: the O-GlcNAcylation may impair actin’s function in some 382 
way, and in turn disrupt the gap junctional communication between the cumulus cells and the 383 
oocyte. This communication is vital for COC maturation (see Chapter 1, section 1.3). Tubulin-α 384 
forms microtubules in the cell, which assist in maintaining cell shape, guiding chromosome 385 
segregation and transport and motility of proteins (Hadfield et al. 2003). In Drosophila 386 
specialised forms of tubulin-α are required for oocyte meiosis and cleavage (Matthews, Rees, 387 
and Kaufman 1993). 388 
Two proteins identified, zona pellucida sperm-binding proteins 2 and 3, are expressed 389 
specifically in the oocyte (Lunsford et al. 1990). While they have not previously been identified 390 
as O-GlcNAcylated, they are known glycoproteins (long-chain type) (Roller and Wassarman 391 
1983), and the glycosylation plays a role in the acrosome reaction of sperm at fertilisation 392 
(Chakravarty et al. 2008).  393 
Glucose-6-phosphate dehydrogenase X is the rate-limiting enzyme of the oxidative phase of the 394 
pentose phosphate pathway (see Chapter 1, 1.3.2), and has previously been identified as O-395 
GlcNAcylated, although it is unknown how this may affect the protein’s function (Gurcel et al. 396 
2008).  397 
Elongation factor 1-α and protein disulfide-isomerase (PDI) are two proteins involved in the 398 
synthesis and processing of new proteins. Elongation factor 1-α catalyses the binding of 399 
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aminoacyl-transfer RNA to the ribosome, regulating the rate of protein elongation during 400 
translation (Condeelis 1995). After translation, PDI catalyses disulfide bond formation (chemical 401 
cross-linking of specific cysteines) during protein folding (Wilkinson and Gilbert 2004). The 402 
roles of O-GlcNAcylated elongation factor 1-α and PDI in the COC have not been investigated, 403 
although it may be speculated that any change in their function would affect the significant 404 
amount of protein synthesis occurring during oocyte maturation. It is interesting to note the 405 
presence of both PDI and heat shock protein 90 (HSP90) in the candidate list, as both are known 406 
to have chaperone roles (Picard 2002; Wilkinson and Gilbert 2004). While PDI is located in the 407 
endoplasmic reticulum and HSP90 is a cytoplasmic protein, the combination of the effect of 408 
excess O-GlcNAc on both of these proteins may mean that inhibition of correct protein assembly 409 
and folding downstream plays a significant role in the effect of hyperglycosylation on COCs and 410 
other cell types.  411 
We focused on HSP90, the two isoforms of which share 86% homology in mice (Moore et al. 412 
1989) and are likely the result of gene duplication as they are structurally and functionally very 413 
similar (Picard 2002). Originally discovered as one of the proteins whose abundance increases 414 
under conditions of heat stress (Picard 2002), an increase in HSP90 levels can be induced in cells 415 
by almost any form of stress, including ethanol and cocaine treatment, acidic pH, nutrient 416 
deprivation and fluctuations in oxygen supply (Gabai and Kabakov 1994; Miles et al. 1994; 417 
Salminen et al. 1997) as well as  during oogenesis in the mouse, turtle and Drosophila 418 
(Zimmerman, Petri, and Meselson 1983; Curci et al. 1991; Barnier et al. 1987; Morange et al. 419 
1984; Harry, Williams, and Briscoe 1990). Western blots of COC proteins immunoprecipitated 420 
with the CTD110.6 antibody confirmed the presence of O-GlcNAcylated HSP90 in glucosamine-421 
treated COCs and the absence of this form of HSP90 in the control and BADGP treatment 422 
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groups. This suggests that under normal maturation conditions HSP90 exists in an un-O-423 
GlcNAcylated form. It was also important to perform Western blots for the total amount of 424 
HSP90 present in each treatment group, because HSP90 is a stress protein and glucosamine is 425 
known to induce stress (Werstuck et al. 2006). However, there were no differences seen in total 426 
HSP90 levels in any treatment group. 427 
Inhibition of HSP90 during oocyte maturation was achieved through the use of 17AAG, an 428 
inhibitor of HSP90 which has been clinically trialed to the phase II stage as a tumour suppressor 429 
in various types of cancer (Modi et al. 2011; Oh et al. 2011).  We found that 17AAG had no 430 
effect on cleavage or blastocyst development rates when added to control media. However, in the 431 
presence of glucosamine (which significantly reduces blastocyst development), 17AAG was able 432 
to recover blastocyst development to rates comparable to control levels. Since levels of total 433 
HSP90 were constant between treatment groups, it is unlikely that 17AAG simply inhibited an 434 
excess of HSP90 in the glucosamine-treated COCs. Together with the Western blot result 435 
showing elevated O-GlcNAcylated HSP90 in glucosamine-treated, but not control or BADGP 436 
treated COCs, it suggests that the function of HSP90 in a O-GlcNAcylated state is detrimental to 437 
oocyte developmental competence. 438 
The experiments conducted in this study are the first to examine levels of O-GlcNAcylation in 439 
the mouse COC during IVM. We also identified potential targets of O-GlcNAcylation in COCs 440 
matured under hyperglycaemic conditions, using the hyperglycaemic mimetic glucosamine. 441 
Inhibition of the O-GlcNAcylated form of HSP90 (one of the most promising candidate proteins) 442 
in glucosamine-treated COCs resulted in an increase of blastocyst rates to control levels, and this 443 
was not due to an increase in the total amount of HSP90. These results are the first to identify 444 
candidate proteins which may be targeted by O-GlcNAcylation in oocytes under hyperglycaemic 445 
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conditions. However, while they are an important step in suggesting a possible mechanism for 446 
the decrease in developmental competence observed under hyperglycaemic conditions, this work 447 
was performed in vitro and needs to be extended through the use of in vivo models. Glucosamine 448 
is commonly used as a hyperglyacemic mimetic, and specifically up-regulates the HBP and 449 
subsequent O-GlcNAcylation, which we have previously shown to be associated with poor 450 
developmental competence of COCs. However, it is not metabolized through other glucose 451 
metabolic pathways (glycolysis and the pentose phosphate pathway), and further work is 452 
currently exploring alternative in vivo models of hyperglycaemia.  453 
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Heat shock protein HSP 90-alpha HS90A_MOUSE 633 Yes [1-3] 
Protein disulfide-isomerase A3 PDIA3_MOUSE 631 No 
Heat shock protein HSP 90-beta HS90B_MOUSE 450 Yes [1, 2] 
Fibronectin FINC_MOUSE 343 No 
Actin, cytoplasmic 1 ACTB_MOUSE 
332 Yes [2-5] 
Actin, cytoplasmic 2 ACTG_MOUSE 
Elongation factor 1-alpha 1 EF1A1_MOUSE 
115 Yes [1-3, 5] 
Elongation factor 1-alpha 2 EF1A2_MOUSE 
Glucose-6-phosphate 1-dehydrogenase 
X 
G6PD1_MOUSE 114 Yes [5] 
Zona pellucida sperm-binding protein 3 ZP3_MOUSE 110 No 
Zona pellucida sperm-binding protein 2 ZP2_MOUSE 101 No 
Tubulin alpha-1A chain TBA1A_MOUSE 
89 Yes [2, 3, 5, 6] Tubulin alpha-1B chain TBA1B_MOUSE 
Tubulin alpha-1C chain TBA1C_MOUSE 
Protein disulfide-isomerase PDIA1_MOUSE 83 








Table 1. Beta-O-linked glycosylated (O-GlcNAcylated) proteins identified in glucosamine-
treated mouse cumulus-oocyte-complexes (COCs) 
100 COCs were collected following 6 h in vitro maturation with glucosamine supplementation, 
proteins were immunoprecipitated using CTD110.6 for O-GlcNAc and identified by mass 
spectrometry. Combined Ion Score is the sum of all individual peptide scores matched to the 
protein. References: 1. Well et al., 2002. 2. Nandi et al., 2006. 3. Teo et al., 2010. 4. Park et al., 






Figure 1 Beta-O-linked glycosylation (O-GlcNAcylation) of proteins in cumulus-
oocyte-complexes (COCs) 
COCs (50 per lane) were cultured in control medium (C), ± 2.5 mM glucosamine (GlcN), ± 2.5 
mM benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP). Proteins were separated 
using SDS-PAGE, Western blotted and probed using the O-GlcNAc antibody CTD110.6 or anti-
β-actin as a loading control. Positive control (+ve) was 0.5 ng BSA-GlcNAc, negative controls 
were 100 ng each BSA and ovalbumin. (A) Representative Western blot. The membrane was cut 
before staining on dotted line shown; areas used for densitometry analysis are shown in white 









Figure 2 Immunocytochemistry of beta-O-linked glycosylation (O-GlcNAcylation) in 
cumulus-oocyte-complexes (COCs) 
COCs were collected after 6 h IVM in control medium ± 2.5 mM glucosamine (GlcN) ± 2.5 mM 
benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP). Propidium iodide (PI, red) 







Figure 3 Total and beta-O-linked glycosylated (O-GlcNAcylated) Heat shock protein 
90 (HSP90) in cumulus-oocyte-complexes (COCs) 
COCs (15 per lane) were collected after 6 h IVM in control medium ± 2.5 mM glucosamine 
(GlcN) ± 2.5 mM benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP). Proteins were 
separated using SDS-PAGE, Western blotted and probed using an anti-HSP90 antibody.  
Positive control (+ve) was 4 µg HeLa cell lysate. (A) Total levels of HSP90. β-actin was used as 
a loading control. (B) Proteins were immunoprecipitated using CTD110.6 for O-GlcNAc prior to 
Western blotting. (C) Immunocytochemical localisation of HSP90 (red) and O-GlcNAcylation 
(green) in glucosamine-treated COCs at various magnifications. 4’,6-Diamidino-2-phenylindole 














Figure 4 Embryo development following inhibition of Heat shock protein 90 (HSP90) 
during in vitro maturation (IVM) 
Cleavage and blastocyst (day 5) rates were assessed, following collection and oocyte maturation 
in control medium ± glucosamine (GlcN; 2.5 mM) and the HSP90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin (17AAG, 0.1 µM). Groups with different superscripts differ 

















Figure 5 Heat shock protein 90 (HSP90) is associated with beta-O-linked N-
acetylglucosamine transferase (OGT) in cumulus-oocyte-complexes (COCs) 
(A) COCs (50 per lane) were immunoprecipitated using anti-OGT, separated using SDS-PAGE, 
Western blotted and probed using an anti-HSP90 antibody. Positive control (+ve) was 4 µg HeLa 
cell lysate. “+ ab” and “- ab” refer to whether or not primary antibody was used for 
immunoprecipitation. (B) Immunocytochemical localisation of HSP90 (green) and OGT (red) in 







SUPPLEMENTARY Figure 1 Preliminary data: beta-O-linked glycosylation (O-
GlcNAcylation) in cumulus-oocyte complexes (COCs) throughout in vitro maturation 
(IVM) 
COCs (50 per lane) were cultured in control medium (C), ± 2.5 mM glucosamine (GlcN), ± 2.5 
mM benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP). Proteins were 
immunoprecipitated using the O-GlcNAc antibody CTD110.6, separated using SDS-PAGE, 
Western blotted and probed using CTD110.6. Positive control (+ve) was 0.5 ng BSA-GlcNAc, 
negative controls were 100 ng each BSA and ovalbumin. (A) Representative Western blot. Areas 
used for densitometry analysis are shown in white boxes and were restricted to > 75 kDa to avoid 






SUPPLEMENTARY Figure 2  Representative controls for 
immunocytochemistry in cumulus-oocyte complexes (COCs) 
COCs were collected after 6 h in vitro maturation in control medium ± 2.5 mM glucosamine 
(GlcN) (no antibody controls performed on glucosamine-treated COCs). Immunocytochemical 
localisation of Heat shock protein 90 (red) and O-GlcNAcylation (green) COCs at 90x 
magnification. 4’,6-Diamidino-2-phenylindole (DAPI) was used for nuclear staining. 
Normoglycaemic and no antibody controls shown. 
